19 April 2013
Karus Therapeutics presenting at BIO, BioTrinity, Anglo-Nordic Biotech and Next-Gen Kinase Inhibitors
Oxford, UK, 19 April 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be making presentations at a number of key trade conferences including:
BIO International Convention, Chicago, USA, 22-25th April: Simon Kerry, CEO, will present at the conference’s BIO Business Forum on 23rd April at 2.15pm (CST) in the Chicago Cubs Room on the topic of autoimmune/inflammation and oncology
BioTrinity 2013, Newbury, Berkshire, UK, 14-16th May: Simon Kerry will open the Inflammation, Immunity and Respiratory session with Karus’s presentation on 16th May at 1:50pm (BST) in Session Room C
Anglo-Nordic Biotech Conference, London, UK, 13th June: Simon Kerry will be presenting an update on the company’s R&D programmes.
Next-Gen Kinase Inhibitors, Boston, USA, 17-19th June: Stephen Shuttleworth, CSO, will present in the Case Study session on 18th June at 4pm (EST) on the topic of the design and development of novel, selective PI3K inhibitors for the treatment of cancer and immune-inflammatory diseases
For more information on Karus’s presentations or for media enquiries, please contact firstname.lastname@example.org.